Please assess the completion status of the following clinical trial:

Trial Title: Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A diffuse glial tumour (high-grade (stage 1), low-grade or high-grade (stage 2)) is suspected from the diagnostic magnetic resonance images (MRI).~* In cases where histopathology is not known from previous biopsy or resection (i.e. diagnosis is suspected based on MRI findings and not from previous surgery) a tissue sample for frozen section is necessary to confirm the diagnosis.~* Karnofsky performance status \>=70~Exclusion Criteria:~* Not able to consent (e.g. severe cognitive impairment)~* Intended biopsy only (meaning: cases not suitable for resection)~* Hypersensitivity to egg protein~* Hypersensitivity to soya or peanut protein~* Hypersensitivity to glycerol~* Pregnancy of breast-feeding~* Intention to become pregnant during the time of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High grade gliomas stage 1 ACF (Type: EXPERIMENTAL): In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
- Low-high grade gliomas stage 2 ACF (Type: EXPERIMENTAL): If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
- High grade gliomas stage 1 control (Type: ACTIVE_COMPARATOR): In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
- Low-high grade gliomas stage 2 control (Type: ACTIVE_COMPARATOR): If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma

Based on this trial design, predict the completion outcome and termination type (if applicable).